ArticleInfectious diseases and therapy2026
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLower respiratory tract disease caused by respiratory syncytial virus (RSV-LRTD) is associated with substantial clinical and economic burden among older adults and adults with chronic medical conditions. Bivalent RSV prefusion F protein-based vaccine (RSVpreF) has been authorized for use among all adults aged ≥ 60 years in the Netherlands, and The Health Council of the Netherlands has recommended RSV vaccination for at-risk persons aged 60-74 years and all persons aged ≥ 75 years. We estimated the cost-effectiveness of implementing this strategy.
methodsWe have developed a static cohort model to demonstrate lifetime clinical and economic outcomes associated with RSV-LRTD among adults in the Netherlands, with (vs. without) RSVpreF use (price: €180; age/risk-specific uptake: 44.6-80.4%). Model inputs include population characteristics, disease rates [hospitalization (RSV-H), general practitioner visit (RSV-GP), non-medically attended (RSV-NMA)], fatality rates, vaccine effectiveness (based on real-world and clinical trial data), utilities/disutilities, medical care costs, indirect costs associated with morbidity- and mortality-related productivity loss, and vaccination costs. Discounting was applied to costs (3%) and benefits (1.5%).
resultsAmong at-risk adults aged 60-74 years and all adults aged ≥ 75 years (n = 4.8 million) in the Netherlands, single-dose RSVpreF would prevent 84,228 RSV-LRTD cases (RSV-H: 16,642, RSV-GP: 21,788, RSV-NMA: 45,798) and 2304 RSV-LRTD deaths over a lifetime horizon. With 11,006 quality-adjusted life-years (QALY) gained and a €195 million increase in total costs, incremental cost-effectiveness ratio for RSVpreF would be €17,740/QALY gained. RSVpreF would thus prevent 16% of hospitalizations, 15% of deaths, 16% of medical costs, and 20% of indirect costs related to RSV among this population over their remaining lifetime. In probabilistic sensitivity analyses applying variability to key inputs, all 1000 replications yielded cost-effectiveness ratios within the Health Council's willingness-to-pay threshold (< €50,000/QALY gained).
conclusionsFindings suggest that RSVpreF would greatly reduce the clinical and economic burden of RSV among older adults in the Netherlands.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.